Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature reviews. Urology

• Publication date

  2018-03-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41585-018-0001-5PMID 29599449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The DNA damage response at dysfunctional telomeres, and at interstitial and subtelomeric DNA double-strand breaks.

  2018cited by this paper
• Liquid biopsy: a step forward towards precision medicine in urologic malignancies

  2017cited by this paper
• A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer

  2017cited by this paper
• Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX

  2016cited by this paper
• Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.

  2016cited by this paper
• Tissue-specific mutation accumulation in human adult stem cells during life

  2016cited by this paper
• Understanding TERT Promoter Mutations: A Common Path to Immortality

  2016cited by this paper
• High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma

  2016cited by this paper
• Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up

  2016cited by this paper
• New prospects for targeting telomerase beyond the telomere

  2016cited by this paper
• Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence

  2016cited by this paper
• KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis

  2016cited by this paper
• Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.

  2016cited by this paper
• The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors

  2016cited by this paper
• Hotspot TERT promoter mutations are rare events in testicular germ cell tumors

  2016cited by this paper
• Telomerase: The Devil Inside

  2016cited by this paper
• A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.

  2016cited by this paper
• Telomerase inhibitors: a patent review (2010–2015)

  2016cited by this paper
• Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.

  2015cited by this paper
• Dynamics of Human Telomerase Holoenzyme Assembly and Subunit Exchange across the Cell Cycle*

  2015cited by this paper
• Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.

  2015cited by this paper
• Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers

  2015cited by this paper
• Variation in cancer risk among tissues can be explained by the number of stem cell divisions

  2015cited by this paper
• TERT promoter mutations in clear cell renal cell carcinoma

  2015cited by this paper
• Abstract B12: GABP selectively binds and activates the mutant TERT promoter across multiple cancer types

  2015cited by this paper
• Cancer-associated TERT promoter mutations abrogate telomerase silencing

  2015cited by this paper
• Complex interactions between the DNA-damage response and mammalian telomeres

  2015cited by this paper
• Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion

  2015cited by this paper
• Recurrent Somatic Mutations in Regulatory Regions of Human Cancer Genomes

  2015cited by this paper
• Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.

  2015cited by this paper
• Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

  2015cited by this paper
• TERT promoter mutations and telomerase reactivation in urothelial cancer

  2015cited by this paper
• How does multistep tumorigenesis really proceed?

  2015cited by this paper
• Telomere Dysfunction, Chromosomal Instability and Cancer.

  2015cited by this paper
• Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition

  2015cited by this paper
• A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells

  2015cited by this paper
• The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer

  2015cited by this paper
• Genome-wide analysis of non-coding regulatory mutations in cancer

  2014cited by this paper
• Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs)

  2014cited by this paper
• Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells

  2014cited by this paper
• Bladder cancers arise from distinct urothelial sub-populations

  2014cited by this paper
• TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling

  2014cited by this paper
• High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins

  2014cited by this paper
• TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR

  2014cited by this paper
• Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

  2014cited by this paper
• Telomerase in bladder cancer: back to a better future?

  2014cited by this paper
• Assessment of DNA Damage and Telomerase Activity in Exfoliated Urinary Cells as Sensitive and Noninvasive Biomarkers for Early Diagnosis of Bladder Cancer in Ex-Workers of a Rubber Tyres Industry

  2014cited by this paper
• Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

  2014cited by this paper
• Telomerase promoter mutations in cancer: an emerging molecular biomarker?

  2014cited by this paper
• Plasticity of In Vitro-Generated Urothelial Cells for Functional Tissue Formation

  2014cited by this paper
• Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.

  2014cited by this paper
• A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration

  2014cited by this paper
• Abstract 2240: TERT promoter mutations are highly prevalent in bladder cancer and represent a potential new urinary biomarker

  2014cited by this paper
• Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions

  2014cited by this paper
• An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity.

  2014cited by this paper
• PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway

  2013cited by this paper
• Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

  2013cited by this paper
• Telomerase Suppresses Formation of ALT-Associated Single-Stranded Telomeric C-Circles

  2013cited by this paper
• The Cancer Genome Atlas Pan-Cancer analysis project

  2013cited by this paper
• TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.

  2013cited by this paper
• CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein‐T mice during mammary carcinogenesis

  2013cited by this paper
• High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

  2013cited by this paper
• The role of telomeres in stem cells and cancer.

  2013cited by this paper
• Abstract 4460: Acquisition of stem cell-like properties during acquired resistance to epidermal growth factor receptor inhibitors.

  2013cited by this paper
• Retinoid signaling in progenitors controls specification and regeneration of the urothelium.

  2013cited by this paper
• Frequency of TERT promoter mutations in human cancers

  2013cited by this paper
• Abstract 4660: A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung cancer.

  2013cited by this paper
• An Investigation of the Effects of the Core Protein Telomerase Reverse Transcriptase on Wnt Signaling in Breast Cancer Cells

  2013cited by this paper
• p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia

  2013cited by this paper
• TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

  2013cited by this paper
• Mitochondrial Telomerase Protects Cancer Cells from Nuclear DNA Damage and Apoptosis

  2013cited by this paper
• TERT Promoter Mutations in Familial and Sporadic Melanoma

  2013cited by this paper
• Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties.

  2013cited by this paper
• Quantitative visualization of DNA G-quadruplex structures in human cells.

  2013cited by this paper
• TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

  2013cited by this paper
• Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence

  2012cited by this paper
• Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions

  2012cited by this paper
• Genetic Variants in Telomere-Maintenance Genes and Bladder Cancer Risk

  2012cited by this paper
• Removal of Shelterin Reveals the Telomere End-Protection Problem

  2012cited by this paper
• Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer.

  2012cited by this paper
• Telomerase directly regulates NF-κB-dependent transcription

  2012cited by this paper
• Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

  2011cited by this paper
• The promoter of human telomerase reverse transcriptase is activated during liver regeneration and hepatocyte proliferation.

  2011cited by this paper
• Altered Telomeres in Tumors with ATRX and DAXX Mutations

  2011cited by this paper
• Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder

  2011cited by this paper
• Immortalisation of normal human urothelial cells compromises differentiation capacity.

  2011cited by this paper
• Phenotypes in mTERT+/− and mTERT−/− Mice Are Due to Short Telomeres, Not Telomere-Independent Functions of Telomerase Reverse Transcriptase

  2011cited by this paper
• Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor

  2010cited by this paper
• Rate, molecular spectrum, and consequences of human mutation

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Dynamics of telomerase activity in response to acute psychological stress.

  2010cited by this paper
• Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers

  2010cited by this paper
• Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

  2010cited by this paper
• G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells

  2009cited by this paper
• Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells.

  2009cited by this paper
• Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication.

  2009cited by this paper
• Crypt stem cells as the cells-of-origin of intestinal cancer

  2009cited by this paper
• Telomerase Is Essential to Alleviate Pif1-Induced Replication Stress at Telomeres

  2009cited by this paper
• Mitochondrial Telomerase Reverse Transcriptase Binds to and Protects Mitochondrial DNA and Function From Damage

  2009cited by this paper
• Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase‐immortalized urothelial cells (TERT‐NHUC)

  2009cited by this paper

• A novel oncogenic nonsense mutation of SMARCA4 and genetic characteristic analysis of SMARCA4 (BRG1)-deficient undifferentiated tumor of the bladder.

  2026cites this paper
• Extra-Gonadal Urinary Tract Neoplasms with Yolk Sac Differentiation: Clinical, Histologic, and Molecular Evidence of Derivation from Underlying Urothelial Carcinoma.

  2025cites this paper
• Review of recent molecular pathology of bladder urothelial carcinoma

  2025cites this paper
• TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma

  2025cites this paper
• Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers

  2025cites this paper
• Diagnostic workout of glandular malignant lesions of the bladder according to the 5th WHO classification

  2025cites this paper
• Frequent BRAF V600E and TERT promoter‐mutated renal epithelial‐predominant Wilms tumours with metanephric features: a distinct subset within the Wilms tumour spectrum?

  2025cites this paper
• Role of telomere maintenance genes as a predictive biomarker for colorectal cancer immunotherapy response and prognosis

  2025cites this paper
• Comprehensive behavioural assessment of TERT in bladder cancer.

  2024cites this paper
• Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature

  2024cites this paper
• Syngeneic mesenchymal stem cells loaded with telomerase-dependent oncolytic adenoviruses enhance anti-metastatic efficacy

  2024cites this paper
• Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors

  2024cites this paper
• TE-RPA: One-tube telomerase extension recombinase polymerase amplification-based electrochemical biosensor for precise diagnosis of urothelial carcinoma.

  2024cites this paper
• Molecular confirmation that fibrocartilaginous dysplasia is a variant of fibrous dysplasia

  2024cites this paper
• An overview of the role of telomeres and telomerase in pre‑neoplastic lesions (Review)

  2023cites this paper
• Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer.

  2023cites this paper
• Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry

  2023cites this paper
• Precision Medicine in Bladder Cancer: Present Challenges and Future Directions

  2023cites this paper
• Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.

  2023cites this paper
• Plasmacytoid urothelial carcinoma - A clinicopathological case series of an aggressive variant of urothelial cancer.

  2023cites this paper
• Telomere maintenance-related genes are important for survival prediction and subtype identification in bladder cancer

  2023cites this paper
• Telomerase: A prominent oncological target for development of chemotherapeutic agents.

  2023cites this paper
• Frequent Telomerase Reverse Transcriptase (TERT) Promoter and Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.

  2023cites this paper
• The TERT Promoter: A Key Player in the Fight for Cancer Cell Immortality

  2023cites this paper
• Assessment of aggressive bladder cancer mutations in plasma cell-free DNA

  2023cites this paper
• Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

  2023cites this paper
• Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations

  2023cites this paper
• Clear Cell Adenocarcinoma of Urethra: Clinical and Pathologic Implications and Characterization of Molecular Aberrations

  2023cites this paper
• Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer

  2023cites this paper
• GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall

  2022cites this paper
• Evaluation of TERT promoter mutations in tumor biopsies and urine sediment of Moroccan bladder cancer patients

  2022cites this paper
• Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer

  2022cites this paper
• Genomics and Immunomics in the Treatment of Urothelial Carcinoma

  2022cites this paper
• A Comparative Assessment of Replication Stress Markers in the Context of Telomerase

  2022cites this paper
• Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.

  2022cites this paper
• Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer

  2022cites this paper
• Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers

  2022cites this paper
• Molecular Characterization of Muellerian Tumors of the Urinary Tract

  2021cites this paper
• Urinary Biomarkers: Current Status and Future Opportunities

  2021cites this paper
• The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers

  2021cites this paper
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

  2021cites this paper
• Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications

  2021cites this paper
• TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers

  2021cites this paper
• From DEPARTMENT OF MEDICINE, SOLNA Karolinska Institutet, Stockholm, Sweden PROMOTER MUTATIONS/METHYLATION IN THYROID AND UROTHELIAL CARCINOMAS: BIOLOGICAL AND CLINICAL IMPLICATIONS

  2021cites this paper
• Shorter Leukocyte Telomere Length Is Associated with Worse Survival of Patients with Bladder Cancer and Renal Cell Carcinoma

  2021cites this paper
• TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer

  2020cites this paper
• HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines

  2020cites this paper
• The expanding molecular and mutational landscape of nested variant of urothelial carcinoma

  2020cites this paper
• Practical Molecular Testing in a Clinical Genitourinary Service.

  2020cites this paper
• Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays.

  2020cites this paper
• Telomeres in toxicology: Occupational health.

  2020cites this paper
• Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase

  2020cites this paper
• Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer

  2020cites this paper
• Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer

  2020cites this paper
• Telomeres and Telomerase in the Development of Liver Cancer

  2020cites this paper
• Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract.

  2019cites this paper
• Urologic Oncology: Seminars and Original Investigations Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays

  2019influential citation
• A Novel Tissue and Stem Cell Specific TERF1 Splice Variant Is Downregulated in Tumour Cells

  2019cites this paper
• Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk

  2019cites this paper
• Aneuploidy-inducing gene knockdowns overlap with cancer mutations and identify Orp3 as a B-cell lymphoma suppressor

  2019cites this paper
• Telomere dynamic in humans and animals: Review and perspectives in environmental toxicology.

  2019cites this paper
• Telomerase reverse transcriptase alterations in human cancers: Diagnosis, prognosis, and therapeutic implications

  2019cites this paper
• Diverse regulatory manners of human telomerase reverse transcriptase

  2019cites this paper
• The role of telomere dysfunction in modulating disease progression and response to treatment in chronic lymphocytic leukaemia.

  2018cites this paper